506509027 02/17/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT6555803

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NORBERT PURRO	06/01/2013
MARK S. SMYTH	06/25/2012
ERICK GOLDMAN	06/25/2012

RECEIVING PARTY DATA

Name:	PHARMACYCLICS INC.	
Street Address:	995 E. ARQUES AVE.	
City:	SUNNYVALE	
State/Country:	CALIFORNIA	
Postal Code:	94085	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16951796

CORRESPONDENCE DATA

Fax Number: (617)832-7000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617) 832-1286

Email: patentdocketing@foleyhoag.com, cmurphy@foleyhoag.com

FOLEY HOAG LLP **Correspondent Name:**

Address Line 1: 155 SEAPORT BOULEVARD

Address Line 4: BOSTON, MASSACHUSETTS 02210-2600

ATTORNEY DOCKET NUMBER:	PIR-95312
NAME OF SUBMITTER:	CARA MURPHY
SIGNATURE:	/Cara Murphy/
DATE SIGNED:	02/17/2021

Total Attachments: 2

source=PIR_95312_Purro_Smyth_Goldman_Assignment#page1.tif source=PIR 95312 Purro Smyth Goldman Assignment#page2.tif

PATENT REEL: 055295 FRAME: 0897 506509027

PATENT ASSIGNMENT	Docket Number: 25922-853.101			
WHEREAS, the undersigned:				
1. PURRO, Norbert 15460 Corinne Drive Los Gatos, CA 95032				
(hereinafter "Inventor(s))," have invented certain new and useful improvements in				
CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASI	E INHIBITOR			
for which a United States patent application is executed on even date herewith; for which Application No. 61/655,381 was filed on June 4, 2012 in the United States Patent Office; for which Application No was filed on in the U.S. Receiving Office of the Patent Cooperation Treaty; for which Application No was filed on in the Patent Office; and/or for which an application was filed upon which a United States Patent issued on, as U.S. Patent No (hereinafter "Application(s)").				
WHEREAS, <u>Pharmacyclics Inc.</u> , a corporation of the State of <u>Delaware</u> , having a place of business at <u>9999</u> (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or se collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other thereon granted in the United States, foreign countries, or under any international convention, agreement,	ion(s) and the inventions disclosed therein, and in everally, by said Inventor(s) (hereinafter r forms of protection (hereinafter "Patent(s)")			
NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignee:	aid Inventor(s) to have been received in full from			
1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the er Inventions and said Applications, including the right to claim priority to said Inventions and said Application and corresponding non-United States patent applications and Patent(s), including those filed under the Par Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any United States, in any foreign country, or under any international convention, agreement, protocol, or treat any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation and to each and every reissue, reexamination, or extensions of any of said Patent(s).	tions; (b) in and to all rights to all United States ris Convention for the Protection of Industrial and all Patent(s) granted on said Inventions in the y, including each and every application filed and			
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable right, title and interest herein conveyed in the United States, foreign countries, or under any international accoperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving a specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desi Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (d) for filing and prosecuting age (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings in therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opporariority contests, public use proceedings, infringement actions and court actions; provided, however, that a providing such cooperation shall be paid for by said Assignee.	convention, agreement, protocol, or treaty. Such of testimony, execution of petitions, oaths, irable by said Assignee (a) for perfecting in said eventions; (c) for filing and prosecuting substitute, oplications for reissuance of any said Patent(s); involving said Inventions and any applications osition proceedings, cancellation proceedings,			
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.				
 Said Inventor(s) hereby warrant and represent that they have not entered and will not understanding in conflict herewith. 	enter into any assignment, contract, or			
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.				
6. This instrument will be interpreted and construed in accordance with the laws of the aw principles. If any provision of this instrument is found to be illegal or unenforceable, the other provision actually the other provision and the same agreement.	ions shall remain effective and enforceable to the			
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said	Assignee as of the dates written below:			
Date: June 1, 2013				

5615675_1.DOC

Date: June 1, 2013

Page 1 of 1

PATENT REEL: 055293 FRAME: 0896

RECORDED: 03/04/2015

		<u> </u>			
	PATENT ASSIGNMENT		Docket Number: 25922-853.101		
WHEREAS, the undersig	gnęd:				
 SMYTH, Mark Rock Harbor Lau Foster City, CA 944 			•		
(hereinafter "Inventor(s))," have invented certain new and useful improvement	ts in			
	CRYSTALLINE FORMS OF A BRUTO	DN'S TYROSINE KINASE	ENHIBITOR		
for which a United States patent application is executed on even date herewith; for which Application No. 61/655.381 was filed on					
WHEREAS, Pharmacyclies Inc., a corporation of the State of Delaware, having a place of business at 995. East Arques Avenue, Sunnyvale, GA 94085, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s) and the inventions disclosed therein, and in and to all embediments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, forcign countries, or under any international convention, agreement, protocol, or treaty.					
NOW, THERE said Assignee:	FORE, in consideration of good and valuable consid	eration acknowledged by sai	id Inventor(s) to have been received in full from		
Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions and said Applications, including the right to claim priority to said Inventions and said Applications; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris-Convention for the Protection of Industrial Property. The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).					
2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign confitries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of perfitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions and any applications free for and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.					
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said inventor(s), their respective heirs, legal representatives and assigns.					
4. Said Inventor(s) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.					
5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.					
6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.					
IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:					
Date: 25.3W 2012	Mark SMYTH I	Date: <u>25 Juny</u> 2012 E	rick GOLDMAN		

Page L of I

RECORDED: 02/04/2025